Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • FDA Expands Market Access, Authorizes New ENDS Products
  • Regulatory

FDA Expands Market Access, Authorizes New ENDS Products

FDA

FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.

Read full story

pharminent May 5, 2026 (Last updated: May 6, 2026)

FDA

FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.

Read full story

Post navigation

Previous: Viridian data lift prospects for thyroid eye disease drug
Next: MSD concludes Terns acquisition to expand CML pipeline

Related Stories

  • Regulatory

Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa

pharminent August 20, 2026
  • Regulatory

Regeneron wins FDA approval to challenge Ipsen for rare bone disease market

pharminent August 20, 2026
  • Regulatory

FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy

pharminent August 20, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.